155 related articles for article (PubMed ID: 34452019)
1. Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer.
Rocconi RP; Stanbery L; Madeira da Silva L; Barrington RA; Aaron P; Manning L; Horvath S; Wallraven G; Bognar E; Walter A; Nemunaitis J
Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452019
[TBL] [Abstract][Full Text] [Related]
2. Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
Walter A; Rocconi RP; Monk BJ; Herzog TJ; Manning L; Bognar E; Wallraven G; Aaron P; Horvath S; Tang M; Stanbery L; Coleman RL; Nemunaitis J
Gynecol Oncol; 2021 Dec; 163(3):459-464. PubMed ID: 34702567
[TBL] [Abstract][Full Text] [Related]
3. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Rocconi RP; Monk BJ; Walter A; Herzog TJ; Galanis E; Manning L; Bognar E; Wallraven G; Stanbery L; Aaron P; Senzer N; Coleman RL; Nemunaitis J
Gynecol Oncol; 2021 Jun; 161(3):676-680. PubMed ID: 33715892
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.
Zhang Y; Zhang L; Zhao Y; Wang S; Feng L
Front Oncol; 2022; 12():945867. PubMed ID: 36338747
[TBL] [Abstract][Full Text] [Related]
5. ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
Rocconi RP; Stanbery L; Tang M; Walter A; Monk BJ; Herzog TJ; Coleman RL; Manning L; Wallraven G; Horvath S; Bognar E; Senzer N; Brun S; Nemunaitis J
Commun Med (Lond); 2022; 2():106. PubMed ID: 36051466
[TBL] [Abstract][Full Text] [Related]
6. Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer.
Barve M; Aaron P; Manning L; Bognar E; Wallraven G; Horvath S; Stanbery L; Nemunaitis J
Clin Med Insights Oncol; 2022; 16():11795549221110501. PubMed ID: 35957960
[TBL] [Abstract][Full Text] [Related]
7. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Rocconi RP; Grosen EA; Ghamande SA; Chan JK; Barve MA; Oh J; Tewari D; Morris PC; Stevens EE; Bottsford-Miller JN; Tang M; Aaron P; Stanbery L; Horvath S; Wallraven G; Bognar E; Manning L; Nemunaitis J; Shanahan D; Slomovitz BM; Herzog TJ; Monk BJ; Coleman RL
Lancet Oncol; 2020 Dec; 21(12):1661-1672. PubMed ID: 33271095
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
Oh J; Barve M; Matthews CM; Koon EC; Heffernan TP; Fine B; Grosen E; Bergman MK; Fleming EL; DeMars LR; West L; Spitz DL; Goodman H; Hancock KC; Wallraven G; Kumar P; Bognar E; Manning L; Pappen BO; Adams N; Senzer N; Nemunaitis J
Gynecol Oncol; 2016 Dec; 143(3):504-510. PubMed ID: 27678295
[TBL] [Abstract][Full Text] [Related]
9. Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.
Ghisoli M; Barve M; Mennel R; Lenarsky C; Horvath S; Wallraven G; Pappen BO; Whiting S; Rao D; Senzer N; Nemunaitis J
Mol Ther; 2016 Aug; 24(8):1478-83. PubMed ID: 27109631
[TBL] [Abstract][Full Text] [Related]
10. Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy.
Sliheet E; Robinson M; Morand S; Choucair K; Willoughby D; Stanbery L; Aaron P; Bognar E; Nemunaitis J
Cancer Gene Ther; 2022 Jul; 29(7):993-1000. PubMed ID: 34785763
[TBL] [Abstract][Full Text] [Related]
11. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680].
Rocconi RP; Monk BJ; Walter A; Herzog TJ; Galanis E; Manning L; Bognar E; Wallraven G; Stanbery L; Aaron P; Senzer N; Coleman RL; Nemunaitis J
Gynecol Oncol; 2023 Feb; 169():173. PubMed ID: 36456375
[No Abstract] [Full Text] [Related]
13. Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6.
Barve V; Adams N; Stanbery L; Manning L; Horvath S; Wallraven G; Bognar E; Barve M; Nemunaitis J
Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696309
[TBL] [Abstract][Full Text] [Related]
14. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy.
Henriksen JR; Nederby L; Donskov F; Waldstrøm M; Adimi P; Jakobsen A; Steffensen KD
J Ovarian Res; 2020 May; 13(1):59. PubMed ID: 32414391
[TBL] [Abstract][Full Text] [Related]
16. CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma.
Khunger A; Piazza E; Warren S; Smith TH; Ren X; White A; Elliott N; Cesano A; Beechem JM; Kirkwood JM; Tarhini AA
PLoS One; 2021; 16(1):e0245287. PubMed ID: 33428680
[TBL] [Abstract][Full Text] [Related]
17. The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
Damotte D; Warren S; Arrondeau J; Boudou-Rouquette P; Mansuet-Lupo A; Biton J; Ouakrim H; Alifano M; Gervais C; Bellesoeur A; Kramkimel N; Tlemsani C; Burroni B; Duche A; Letourneur F; Si H; Halpin R; Creasy T; Herbst R; Ren X; Morel P; Cesano A; Goldwasser F; Leroy K
J Transl Med; 2019 Nov; 17(1):357. PubMed ID: 31684954
[TBL] [Abstract][Full Text] [Related]
18. Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer.
Li J; Yue H; Yu H; Lu X; Xue X
BMC Cancer; 2021 Jan; 21(1):67. PubMed ID: 33446144
[TBL] [Abstract][Full Text] [Related]
19. Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.
Brewer M; Angioli R; Scambia G; Lorusso D; Terranova C; Panici PB; Raspagliesi F; Scollo P; Plotti F; Ferrandina G; Salutari V; Ricci C; Braly P; Holloway R; Method M; Madiyalakan M; Bayever E; Nicodemus C
Gynecol Oncol; 2020 Mar; 156(3):523-529. PubMed ID: 31916979
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer.
Liao JB; Swensen RE; Ovenell KJ; Hitchcock-Bernhardt KM; Reichow JL; Apodaca MC; D'Amico L; Childs JS; Higgins DM; Buening BJ; Goff BA; Disis ML
Gynecol Oncol; 2017 Mar; 144(3):480-485. PubMed ID: 28089377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
